Adimab and Gilead have initiated a pharma partnering research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against up to two targets selected by Gilead.
The pharma partnering agreement gives Gilead the option to commercialize antibodies generated from the collaboration.
Under the terms of the pharma partnering agreement, Adimab will receive upfront payments and preclinical milestones.
In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Gilead Sciences
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity